Can Biometrics Solve the Refugee Debate?
By Katie Worth,
PBS Frontline
| 12. 02. 2015
Untitled Document
Of all the doors into the United States, the one that refugees must pass through is perhaps the most closely guarded of all: The years-long application process involves long interviews, background checks and health screenings. Refugees’ inked fingerprints are checked against databases maintained by the FBI, the Department of Defense and the Department of Homeland Security.
New developments in biometrics may add yet more steps to this process: An eyeball scan is likely to become protocol within weeks, and Homeland Security is developing a quick-turnaround DNA test that can be used in field offices.
These technological advances are arriving just as the ongoing refugee crisis in Europe and last month’s deadly attack on Paris has stirred a national debate over whether the U.S. should accept refugees from Syria. Already, more than two dozen U.S. governors have said they do not want Syrian refugees to relocate into their states. And following the attack, a bipartisan majority in the House passed legislation that would require the Department of Homeland Security, the Director of National Intelligence and the FBI to each sign off on security clearances for...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...